EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Contributions of amyloid beta and cerebral small vessel disease in clinical decline

Justine E F Moonen iD, Renée Haan, Isabelle Bos, Charlotte Teunissen, Elsmarieke van de Giessen, Jori Tomassen, Anouk den Braber, Sophie M van der Landen, Eco J C de Geus, Nienke Legdeur, Argonde C van Harten, Calvin Trieu und 5 weitere

Alzheimer's & Dementia · 2024-03 · 20 (3) · 1868-1880

DOI: 10.1002/alz.13607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 25.12.2023. Verfasst von Justine E F Moonen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Cognition Disorders, Cerebral Small Vessel Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw, Hartstichting.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We assessed whether co‐morbid small vessel disease (SVD) has clinical predictive value in preclinical or prodromal Alzheimer's disease. METHODS In 1090 non‐demented participants (65.4 ± 10.7 years) SVD was assessed with magnetic resonance imaging and amyloid beta (Aβ) with lumbar puncture and/or positron emission tomography scan (mean follow‐up for cognitive function 3.1 ± 2.4 years). RESULTS Thirty‐nine percent had neither Aβ nor SVD (A–V–), 21% had SVD only (A–V+), 23% Aβ only (A+V–), and 17% had both (A+V+). Pooled cohort linear mixed model analyses demonstrated that compared to A–V– (reference), A+V– had a faster rate of cognitive decline. Co‐morbid SVD (A+V+) did not further increase rate of decline. Cox regression showed that dementia risk was modestly increased in A–V+ (hazard ratio [95% confidence interval: 1.8 [1.0–3.2]) and most strongly in A+ groups. Also, mortality risk was increased in A+ groups. DISCUSSION In non‐demented persons Aβ was predictive of cognitive decline, dementia, and mortality. SVD modestly predicts dementia in A–, but did not increase deleterious effects in A+. Highlights Amyloid beta (Aβ; A) was predictive for cognitive decline, dementia, and mortality. Small vessel disease (SVD) had no additional deleterious effects in A+. SVD modestly predicted dementia in A–. Aβ should be assessed even when magnetic resonance imaging indicates vascular cognitive impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionCognition DisordersCerebral Small Vessel DiseasesDementia, VascularHumansAmyloid beta-PeptidesMagnetic Resonance Imaging

Stichwörter der Autor:innen

amyloid betacognitive declinedementiamortalitysmall vessel disease

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
  • Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.
  • Nivel, Research Institute for Better Care, Utrecht, the Netherlands.
  • Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands.
  • Department of Biological Psychology, VU University, Amsterdam, the Netherlands.

ORCID-Profile: Justine E F Moonen

Förderung

  • ZonMw
  • Hartstichting

Zitieren

APA

Moonen, J. E. F., Haan, R., Bos, I., Teunissen, C., van de Giessen, E., Tomassen, J., den Braber, A., van der Landen, S. M., de Geus, E. J. C., Legdeur, N., van Harten, A. C., Trieu, C., de Boer, C., Kroeze, L., Barkhof, F., Visser, P. J., & van der Flier, W. M. (2024). Contributions of amyloid beta and cerebral small vessel disease in clinical decline. Alzheimer's & Dementia, 20(3), 1868-1880. https://doi.org/10.1002/alz.13607

Vancouver

Moonen JEF, Haan R, Bos I, Teunissen C, van de Giessen E, Tomassen J, et al. Contributions of amyloid beta and cerebral small vessel disease in clinical decline. Alzheimer's & Dementia. 2024;20(3):1868-1880. doi:10.1002/alz.13607

BibTeX
@article{Moonen2024,
  author = {Moonen, Justine E F and Haan, Renée and Bos, Isabelle and Teunissen, Charlotte and van de Giessen, Elsmarieke and Tomassen, Jori and den Braber, Anouk and van der Landen, Sophie M and de Geus, Eco J C and Legdeur, Nienke and van Harten, Argonde C and Trieu, Calvin and de Boer, Casper and Kroeze, Lior and Barkhof, Frederik and Visser, Pieter Jelle and van der Flier, Wiesje M},
  title = {Contributions of amyloid beta and cerebral small vessel disease in clinical decline},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {3},
  pages = {1868--1880},
  doi = {10.1002/alz.13607}
}
Kostenlos starten →